SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett(Harvard University), Barney S. Graham(National Institutes of Health)
Cited by 1,640
Related Papers
Animal models for COVID-19
|Nature|2020|877
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Next-generation influenza vaccines: opportunities and challenges
|Nature Reviews Drug Discovery|2020|333
Evaluation of candidate vaccine approaches for MERS-CoV
|Nature Communications|2015|313